Secondary Logo

Institutional members access full text with Ovid®

Newly Categorized Seromucinous Tumor of the Ovary

Magnetic Resonance Imaging Findings

Han, Jin Woo, MD*; Kim, Kyeong Ah, MD*; Chang, Hye Yoon, MD; Kim, Jeong Woo, MD*; Park, Yang Shin, MD*; Lee, Jongmee, MD*; Choi, Jae Woong, MD*; Lee, Chang Hee, MD*; Park, Cheol Min, MD*

Journal of Computer Assisted Tomography: January/February 2019 - Volume 43 - Issue 1 - p 119–127
doi: 10.1097/RCT.0000000000000776
Abdominal Imaging

Objective The aim of this study was to describe magnetic resonance imaging findings of newly categorized ovarian seromucinous tumors.

Methods We retrospectively reviewed the images of 29 patients with seromucinous tumor for the following factors: size, configuration, signal intensity (SI), and accompanying ovarian endometriosis.

Results Thirty-two tumors (17 benign, 7 borderline, 8 carcinoma) were found on computed tomography or magnetic resonance imaging. Their mean size was 11.4 cm. Benign tumors appeared as unilocular or multilocular cystic masses. Borderline tumors and carcinomas appeared as complex cystic-solid masses. T2-weighted SI of the solid portion was hyperintense in borderline tumors and intermediate in carcinomas. Endometriosis was present in 18 tumors, and hemorrhage (on images) in 20.

Conclusions The imaging features of seromucinous tumors varied by tumor type. More than half of tumors were accompanied by endometriosis. High T2-weighted SI of the solid portion could be a specific feature of borderline tumors. It is hard to differentiate seromucinous carcinomas from other endometriosis-related carcinomas.

From the Departments of *Radiology and

Pathology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

Received for publication February 14, 2018; accepted May 24, 2018.

Correspondence to: Kyeong Ah Kim, MD, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea (e-mail:

This study was supported by Korea University Grant and grant from the Department of Radiology, Korea University (KUMCRG 08162).

The authors declare no conflict of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.